Mecasermin rinfabate is under clinical development by Oak Hill Bio and currently in Phase II for Hemorrhage. According to GlobalData, Phase II drugs for Hemorrhage have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mecasermin rinfabate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mecasermin rinfabate overview
Mecasermin rinfabate (Iplex) is a recombinant human biologic protein complex of insulin-like growth factor-1 (IGF-1). It is formulated as injectable solution for subcutaneous route of administration. It is indicated in the treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD).
Mecasermin rinfabate (Iplex) is under development for treatment of chronic respiratory morbidity (CRM) including bronchopulmonary dysplasia (BPD). It was also under development for the treatment of burns, myotonic dystrophy, Rabson–Mendenhall syndrome, Leprechaunism, retinopathy of prematurity and severe intraventricular hemorrhage, Laron syndrome, type A and type B extreme insulin resistance syndrome.
Oak Hill Bio overview
Oak Hill Bio is a clinical-stage neonatology and rare disease therapeutics company that develops medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The company offers a pipeline of clinical and preclinical investigational therapeutics and innovation to drug development space. The company pipeline includes OHB-607 bronchopulmonary dysplasia, OHB-101 Immune thrombocytopenia, systemic lupus erythematosus, OHB-401 diabetic macular edema, OHB-201 autoimmune, OHB-211 autoimmune, OHB-301 autoimmune. Oak Hill Bio product indications include bronchopulmonary dysplasia, immune thrombocytopenia, systemic lupus erythematosus diabetic macular edema, and various autoimmune diseases. It operates in the US and the UK. Oak Hill Bio is headquartered in Cheshire, England, the UK.
For a complete picture of Mecasermin rinfabate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
